KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients
- 1 December 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 99 (12), 2903-2909
- https://doi.org/10.1007/s00277-020-04158-4
Abstract
From April 2016, carfilzomib, in combination with lenalidomide and dexamethasone (KRD), became available for use in the daily practice in Italy for patients with relapsed or refractory multiple myeloma (RRMM). We performed a retrospective survey at 14 different institutions from Southern Italy in order to evaluate patient characteristics and treatment results from an unselected series of patients treated accordingly so far. One hundred and twenty-three consecutive patients were included, with a median of 2 previous lines of therapy (range 1-9) and a median age of 63 years (range 39-82). At the time of analysis, median number of courses administered is 11 (range 1-34), and all patients are evaluable for response. Overall response rate including complete remission, very good partial remission, and partial remission is 85%. After a median follow-up of 27 months, median overall and progression-free survival are 33 and 23 months, respectively. Sixty-three patients are alive and between them, 45 (37%) are in continuous remission. Sixty patients have died (49%), mainly from progressive disease. There were 6 treatment-related deaths (5% of the whole patient population). Overall, hematological and non-hematological toxicity were manageable, mostly on outpatient basis. Arterial hypertension has been observed in 43 cases (35%) but did not lead to treatment interruption. Our data demonstrate that in real life, KRD is highly effective and well tolerated in the majority of patients with RRMM.This publication has 19 references indexed in Scilit:
- The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior TherapyThe Oncologist, 2017
- Cardiac and renal complications of carfilzomib in patients with multiple myelomaBlood Advances, 2017
- Practical Considerations in Managing Relapsed Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2016
- Progress and Paradigms in Multiple MyelomaClinical Cancer Research, 2016
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaThe New England Journal of Medicine, 2016
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyThe Lancet Oncology, 2015
- Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational studyBritish Journal of Haematology, 2015
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2015
- Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaBlood, 2013
- Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple MyelomaClinical Cancer Research, 2013